Oncology
ASCO 2026: All about DNA damage response, with Luke Piggot
Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
News
NICE aims to cut funding for Amgen lung cancer drug Lumykras
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
News
Roche looks to Astex in $515m breast cancer deal
Roche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.
News
Novartis snaps up UK ADC developer Myricx Bio
Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.
News
Olympic cyclist Chris Hoy praises cancer charity campaign
Sir Chris Hoy has said he is proud of participants in the Tour de 4 cycling event he set up last year to change perceptions of stage 4 cancer.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
